Given that MECP2 is a dosage-sensitive gene, where excessive silencing may lead to the development of Rett syndrome, fine-tuning the extent of silencing is critical for therapeutic development for MECP2 duplication syndrome (MDS)(2). This evidence concerns the gene MECP2 and atypical Rett syndrome.